Predicting response to radiotherapy of head and neck squamous cell carcinoma using radiomics from cone-beam CT images. (2nd January 2022)

• Record Type: Journal Article
• Authors: Sellami, S.; Bourbonne, V.; Hatt, M.; Tixier, F.; Bouzid, D.; Lucia, F.; Pradier, O.; Goasduff, G.; Visvikis, D.; Schick, U.
• Is Part Of: Acta oncologica. Volume 61:Number 1(2022)
• Page Start: 73
• Page End: 80
• Publication Date: 2022-01-02
• Subjects: CBCT -- head and neck cancers -- radiotherapy -- radiomics -- texture; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2021.1983207
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Introduction: Radiotherapy (RT) for head and neck cancer is now guided by cone-beam computed tomography (CBCT). We aim to identify a CBCT radiomic signature predictive of progression to RT. Material and methods: A cohort of 93 patients was split into training ( n = 60) and testing ( n = 33) sets. A total of 88 features were extracted from the gross tumor volume (GTV) on each CBCT. Receiver operating characteristic (ROC) curves were used to determine the power of each feature at each week of treatment to predict progression to radio(chemo)therapy. Only features with AUC > 0.65 at each week were pre-selected. Absolute differences were calculated between features from each weekly CBCT and baseline CBCT1 images. The smallest detectable change ( C = 1.96 × SD, SD being the standard deviation of differences between feature values calculated on CBCT1 and CBCTn) with its confidence interval (95% confidence interval [CI]) was determined for each feature. The features for which the change was larger than C for at least 5% of patients were then selected. A radiomics-based model was built at the time-point that showed the highest AUC and compared with models relying on clinical variables. Results: Seven features had an AUC > 0.65 at each week, and six exhibited a change larger than the predefined CI 95%. After exclusion of inter-correlated features, only one parameter remains, Coarseness. Among clinical variable, only hemoglobin value was significant. AUC for predicting the treatment response were 0.78 ( p = .006), 0.85 ( p < .001), and 0.99 ( p < .001) for clinical, CBCT4-radiomics (Coarseness) and clinical + radiomics based models respectively. The mean AUC of this last model on a 5-fold cross-validation was 0.80 (±0.09). On the testing cohort, the best prediction was given by the combined model (balanced accuracy [BAcc] 0.67, p < .001). Conclusions: We described a feature selection methodology for delta-radiomics that is able to select reproducible features which are informative due to their change during treatment. A selected delta radiomics feature may improve clinical-based prediction models.